Publications by authors named "Helen Moon"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

603

Total Likes

450

Extended Reach

3,992,965

Social Features

198
N
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.
David J Einstein, Melissa L Abel, Jeanny B Aragon-Ching, Philip M Arlen, Karen A Autio, Helen Moon

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early real-world utilization of avelumab switch maintenance among patients with advanced urothelial carcinoma without progression following treatment with first-line platinum-based chemotherapy.
Helen H Moon, Jeanny B Aragon-Ching, Allison Thompson, Anup Abraham, Anna Vlahiotis

Urol Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Podcast on Real-World Evidence with Avelumab First-Line Maintenance and Treatment Sequencing in Locally Advanced or Metastatic Urothelial Carcinoma.
Petros Grivas, Helen H Moon

Target Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Noninterventional retrospective study of standard-of-care systemic treatment patterns and outcomes in US patients with advanced urothelial carcinoma.
Helen H Moon, Melissa Kirker, Anup Abraham, Anna Vlahiotis, Abhijeet Bhanegaonkar

Oncologist· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Retrospective Study of Clinical and Economic Outcomes Among Patients with Locally Advanced or Metastatic Urothelial Carcinoma Treated with First-Line Systemic Anti-Cancer Therapies in the United States: Results from the IMPACT UC-III Study.
Helen H Moon, Chiemeka Ike, Ruth W Dixon, Christopher L Crowe, Malvika Venkataraman

Curr Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proceedings of the seventh annual Women in Melanoma Conference.
Yana G Najjar, Marlana Orloff, Tara C Mitchell, Tawnya L Bowles, Allison Betof Warner, Helen Moon

Ther Adv Med Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer.
Randy F Sweis, Gurkamal S Chatta, Rohit K Jain, Helen Moon, Scott Edward Delacroix

Clin Cancer Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma: Results From the Real-World US PATRIOT-II Study.
Petros Grivas, Pedro Barata, Helen Moon, Shilpa Gupta, Thomas Hutson

Clin Genitourin Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study.
Toni K Choueiri, Laurence Albiges, Philippe Barthélémy, Roberto Iacovelli, Sheik Emambux, Helen Moon

Lancet· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Treatment Patterns, Sequencing, and Outcomes in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Receiving Avelumab First-Line Maintenance in the United States.
Helen H Moon, Mairead Kearney, Seyed Hamidreza Mahmoudpour, Chiemeka Ike, Valerie Morris

Curr Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study.
Mohamad E Allaf, Se-Eun Kim, Viraj Master, David F McDermott, Lauren C Harshman, Helen H Moon

Lancet Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Shilpa Gupta, Helen H-S Moon, Srikala S Sridhar

Target Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.
Matthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes, Daniel P Petrylak, Thomas W Flaig, Helen H Moon

J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
Peter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, Christopher J Hoimes, Thomas W Flaig, Helen H Moon

J Clin Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
Matthew R Smith, Shahneen Sandhu, Daniel J George, Kim Nguyen Chi, Fred Saad, Helen Moon

J Manag Care Spec Pharm· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
Michael B Atkins, Sandra J Lee, Bartosz Chmielowski, Ahmad A Tarhini, Gary I Cohen, Helen H Moon

J Clin Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-related Adverse Effects Associated with Programmed Death-1 Inhibitor Therapy in the Treatment of Non-Small Cell Lung Cancer: Incidence, Management, and Effect on Outcomes.
Timothy Chiu, Christopher Yamamoto, Fang Niu, Helen Moon, Thach-Giao Truong

Perm J· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pharmacist based intervention to improve the care of patients with CKD: a pragmatic, randomized, controlled trial.
Danielle Cooney, Helen Moon, Yang Liu, Richard Tyler Miller, Adam Perzynski

BMC Nephrol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis